Dejan Juric

Active 2005–2025

139
Papers
19,373
Citations
59
h-index
128
i10-index

Citations

Citations per year for Dejan Juric1999: 1 citations2001: 1 citations2005: 3 citations2006: 16 citations2007: 16 citations2008: 27 citations2009: 23 citations2010: 39 citations2011: 36 citations2012: 43 citations2013: 65 citations2014: 86 citations2015: 117 citations2016: 107 citations2017: 163 citations2018: 150 citations2019: 577 citations2020: 939 citations2021: 1,266 citations2022: 1,191 citations2023: 1,022 citations2024: 1,563 citations2025: 991 citations2026: 49 citations2000: no citations, so this year is not shown2002–2004: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,027 citing papers, 27.8% of this breakdownChina: 1,301 citing papers, 12% of this breakdownUnited Kingdom: 638 citing papers, 5.9% of this breakdownItaly: 614 citing papers, 5.6% of this breakdownGermany: 546 citing papers, 5% of this breakdownFrance: 443 citing papers, 4.1% of this breakdownSpain: 391 citing papers, 3.6% of this breakdownCanada: 341 citing papers, 3.1% of this breakdownJapan: 305 citing papers, 2.8% of this breakdownAustralia: 239 citing papers, 2.2% of this breakdownSwitzerland: 238 citing papers, 2.2% of this breakdownSouth Korea: 215 citing papers, 2% of this breakdown
0%27.8%Other 23.7%

Fields

  • Medicine52.4%
  • Biochemistry, Genetics and Molecular Biology36.7%
  • Computer Science4.4%
  • Immunology and Microbiology3.2%
  • Engineering0.7%
  • Neuroscience0.6%
  • Other2%

Topics

  • Advanced Breast Cancer Therapies5.5%
  • Cancer Genomics and Diagnostics5.1%
  • HER2/EGFR in Cancer Research4.5%
  • PI3K/AKT/mTOR signaling in cancer3.7%
  • Lung Cancer Treatments and Mutations2.7%
  • Cancer-related Molecular Pathways2.6%
  • Other75.9%

Coauthors

All papers

Open in search
  1. Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 cited by 2,572

  2. Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 cited by 468

  3. Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation

    Authors: , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2021 cited by 517

  4. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Malika Sud, Victoria M. Tran, Shamsudheen Karuthedath Vellarikkal, Yiping Wang, Liat Amir-Zilberstein, Deepak Atri, Joseph Beechem, Olga R. Brook, Jonathan Chen, Prajan Divakar, Phylicia Dorceus, J Engreitz, Adam L. Essene, Donna M. Fitzgerald, Robin Fropf, Steven Gazal, Joshua Gould, John Grzyb, Tyler Harvey, Jonathan L. Hecht, Tyler Hether, Judit Jané‐Valbuena, Michael Leney-Greene, Hui Ma, Cristin McCabe, Daniel E. McLoughlin, Eric Miller, Christoph Muus, Mari Niemi, Robert F. Padera, Liuliu Pan, Deepti Pant, Carmel Pe’er, Jenna Pfiffner-Borges, Christopher J. Pinto, Jacob Plaisted, Jason Reeves, Marty Ross, Melissa A. Rudy, Erroll H. Rueckert, Michelle Siciliano, Alexander Sturm, Ellen Todres, Avinash Waghray, Sarah Warren, Shuting Zhang, Daniel R. Zollinger, Lisa A. Cosimi, Rajat M. Gupta, Nir Hacohen, Hanina Hibshoosh, Winston Hide, Alkes L. Price, Jayaraj Rajagopal, Purushothama Rao Tata, Stefan Riedel, Gyöngyi Szabó, Timothy L. Tickle, Patrick T. Ellinor, Deborah T. Hung, Pardis C. Sabeti, Richard Novák, Robert Rogers, Donald E. Ingber, Z. Gordon Jiang, Dejan Juric, Mehrtash Babadi, Samouil L. Farhi, Benjamin Izar, James R. Stone and 9 more - Nature 2021 cited by 883

  5. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

    Authors: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2020 cited by 599

  6. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

    Authors: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 cited by 349

  7. Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2021 cited by 223

  8. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jason E. Faris, Jennifer Y. Wo, François Aguet, Ipsita Dey‐Guha, Mehlika Hazar-Rethinam, Dora Dias‐Santagata, David T. Ting, Andrew X. Zhu, Theodore S. Hong, Todd R. Golub, A. John Iafrate, Viktor A. Adalsteinsson, Alberto Bardelli, Laxmi Parida, Dejan Juric, Gad Getz, Ryan B. Corcoran - Nature Medicine 2019 cited by 522

  9. HER kinase inhibition in patients with HER2- and HER3-mutant cancers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alexander Drilon, James J. Harding, Gopa Iyer, Barry S. Taylor, Michael F. Berger, Richard E. Cutler, Feng Xu, Anna Butturini, Lisa D. Eli, Grace Mann, Cynthia Farrell, Alshad S. Lalani, Richard Bryce, Carlos L. Arteaga, Funda Meric‐Bernstam, José Baselga, David B. Solit - Nature 2018 cited by 788

  10. Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nabeel Bardeesy, Andrew X. Zhu - Cancer Discovery 2016 cited by 545

  11. Targeting TBK1 to overcome resistance to cancer immunotherapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Xingping Qin, Kristopher A. Sarosiek, Gao Zhang, Jong Wook Kim, Mack Y. Su, Angelina M. Cicerchia, Martin Q. Rasmussen, Samuel J. Klempner, Dejan Juric, Sara I. Pai, David M. Miller, Anita Giobbie‐Hurder, Jonathan Chen, Karin Pelka, Dennie T. Frederick, Susanna Stinson, Elena V. Ivanova, Amir Reza Aref, Cloud P. Paweletz, David A. Barbie, Debattama R. Sen, David E. Fisher, Ryan B. Corcoran, Nir Hacohen, Peter K. Sorger, Keith T. Flaherty, Genevieve M. Boland, Robert T. Manguso, Russell W. Jenkins - Nature 2023 cited by 167

  12. Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2024 cited by 237

  13. Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2024 cited by 159

  14. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robin Kate Kelley, Alberto Bardelli, A. John Iafrate, William C. Hahn, Cyril H. Benes, David T. Ting, Hiroshi Hirai, Gad Getz, Dejan Juric, Andrew X. Zhu, Ryan B. Corcoran, Nabeel Bardeesy - Cancer Discovery 2019 cited by 371

  15. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 cited by 409

  16. Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2018 cited by 439

  17. PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2019 cited by 269

  18. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2022 cited by 139

  19. Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity

    Authors: , , , , , , , , , , - Cell chemical biology 2019 cited by 255

  20. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2014 cited by 590

  21. CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors

    Authors: , , , , , , , , , , , , , , , , , , , - Cancer Cell 2014 cited by 439

  22. Deep learning enables genetic analysis of the human thoracic aorta

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Genetics 2021 cited by 207

  23. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial

    Authors: , , , , , , , , , , , , , , , - Annals of Oncology 2020 cited by 145

  24. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

    Authors: , , , , , , , , , , , , , , , , , , - Annals of Oncology 2020 cited by 187